Analytics That Matter in Biosimilar Development
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Analytics That Matter in Biosimilar Development
-
Narrated by:
-
By:
In this episode of Chromatography Life, Neil Lander and Colette Quinn, Sr. Director of Light Scattering in QC at Waters Corporation break down how the October 2025 FDA draft guidance is reshaping expectations for biosimilar development. They explore why LC and orthogonal techniques like MALS are becoming essential for demonstrating analytical similarity and reducing reliance on clinical studies. Colette also highlights how tools like Empower™ Software support data integrity, reproducibility, and faster development timelines.
No reviews yet